MBX

MBX Biosciences, Inc. MBX

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-37.09M

Quarter to Jun 30

Free cash flow

$-23.52M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$3.06B total
Frazier Life Sciences Management, L.P.
$367.19M0.0%
FMR LLC
$293.82M+81.3%
WELLINGTON MANAGEMENT GROUP LLP
$274.76M+55.9%
NEA Management Company, LLC
$199.52M0.0%
ORBIMED ADVISORS LLC
$189.27M-5.7%
BlackRock, Inc.
$183.47M+13.0%
Paradigm Biocapital Advisors LP
$138.44MNew
NVP Associates, LLC
$117.93M0.0%
Deep Track Capital, LP
$95.64M-37.2%
Polar Capital Holdings Plc
$88.79M-0.8%
VANGUARD CAPITAL MANAGEMENT LLC
$81.55M0.0%
Aaron Wealth Advisors LLC
$64.46M0.0%
DRIEHAUS CAPITAL MANAGEMENT LLC
$58.32M+3.8%
Kynam Capital Management, LP
$51.60M0.0%
Woodline Partners LP
$49.69M0.0%
EVENTIDE ASSET MANAGEMENT, LLC
$48.22M-1.9%
STATE STREET CORP
$47.72M+9.8%
PRICE T ROWE ASSOCIATES INC /MD/
$44.98M-20.8%
Parkman Healthcare Partners LLC
$44.17M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$42.68M+15.3%
BRAIDWELL LP
$39.24M-52.4%
TCG Crossover Management, LLC
$35.88M0.0%
Cormorant Asset Management, LP
$30.36M-50.9%
Soleus Capital Management, L.P.
$28.44M+188.0%
GOLDMAN SACHS GROUP INC
$25.34M+0.2%
See all 173 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/MBX

Earnings Per Share

13fpro.ai/company/MBX

Loading ratio trend…

MBX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About MBX Biosciences, Inc. (MBX): stock profile, AI score and financials

MBX Biosciences, Inc. (MBX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. MBX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), MBX Biosciences, Inc. reports net income of $-37.1M, free cash flow of $-23.5M. Top institutional holders of MBX by reported 13-F value include Frazier Life Sciences Management, L.P., FMR, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. MBX trades on the Nasdaq exchange and files with the SEC under CIK 1776111. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MBX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MBX Biosciences, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1776111 →